肝轉移治療市場 - 按藥物類別（標靶治療、化療、免疫治療）、原發性癌症（結直腸癌、乳癌、肺癌）、配銷通路（醫院藥房、專業藥房）、全球預測（2024 - 2032 ）

Liver Metastases Treatment Market - By Drug Class (Targeted Therapy, Chemotherapy, Immunotherapy), Primary Cancer (Colorectal, Breast, Lung), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies), Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受大腸直腸癌和乳癌等通常轉移至肝臟的原發性癌症發生率上升的推動，2024年至2032年全球肝轉移治療市場的複合年成長率將超過6.7%。根據美國癌症協會的數據，2023 年美國將診斷出約 149,500 例結直腸癌新病例和 297,790 例乳腺癌新病例。免疫療法和微創手術技術，可改善患者的治療效果並減少副作用。

此外，醫療保健支出的增加、人們對早期診斷和治療重要性的認知不斷提高以及專業醫療保健服務的不斷擴大，正在進一步推動市場成長。製藥公司正在大力投資研發以推出新療法，而有利的監管政策正在加快新療法的核准流程。這些因素共同塑造了市場動態。

肝轉移治療市場根據藥物類別、原發癌症、配銷通路和地區進行分類。

由於標靶肝轉移的功效以及藥物配方和遞送機制的進步，到 2032 年，化療領域將經歷顯著的複合年成長率。化療藥物在控制腫瘤生長和延長患者存活率方面顯示出顯著改善。更個人化和有針對性的化療方案的開發提高了治療效果並減少了副作用，使這些藥物成為治療肝轉移的首選。

由於乳癌患者轉移進展發生率不斷增加，到 2032 年，乳癌細分市場將佔據顯著的肝轉移治療市場。隨著早期發現和治療提高存活率，越來越多的患者能夠活到癌症轉移到肝臟的程度。這凸顯了對針對肝轉移的有效治療的更大需求。此外，個人化醫療和標靶治療的進步進一步提高了乳癌肝轉移的治療效果。

由於人口老化和癌症發生率上升，歐洲肝轉移治療產業在預測期內將錄得良好的複合年成長率。醫療保健基礎設施的增強和先進醫療技術的普及提高了診斷能力，從而實現更早的檢測和更有效的治療選擇。該地區的醫療保健政策著重於個人化治療方法，刺激了創新療法的採用。癌症研發資金的增加有助於提供新的和改進的治療方式，從而促進區域市場的成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AstraZeneca
Bayer AG
Bristol-Myers Squibb Company
Cadila Pharmaceuticals Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Ono Pharmaceutical
Pfizer, Inc.

簡介目錄

Product Code: 9582

Global Liver Metastases Treatment Market will register over 6.7% CAGR from 2024 to 2032, driven by the rising incidence of primary cancers, such as colorectal and breast cancer, which commonly metastasize to the liver. According to the American Cancer Society, approximately 149,500 new cases of colorectal cancer and 297,790 new cases of breast cancer were diagnosed in the United States in 2023. Advancements in medical technology and oncology research have led to the development of innovative treatment modalities, including targeted therapies, immunotherapies, and minimally invasive surgical techniques, which offer improved patient outcomes and reduced side effects.

Additionally, increasing healthcare expenditure, growing awareness about the importance of early diagnosis and treatment, and the expanding availability of specialized healthcare services are further propelling market growth. Pharmaceutical companies are investing heavily in R&D to introduce novel therapies, while favorable regulatory policies are accelerating the approval process for new treatments. These factors combinedly shape the market dynamics.

The liver metastases treatment market is sorted based on drug class, primary cancer, distribution channel, and region.

The chemotherapy segment will experience a remarkable CAGR through 2032, because of efficacy in targeting liver metastases, linked with advancements in drug formulations and delivery mechanisms. Chemotherapy drugs have shown significant improvements in controlling tumor growth and extending patient survival rates. The development of more personalized & targeted chemotherapy options has enhanced treatment outcomes and reduced side effects, making these drugs a preferred choice in managing liver metastases.

The breast cancer segment will clutch a notable liver metastases treatment market share by 2032, owing to the increasing incidence of metastatic progression in breast cancer patients. As survival rates improve with early detection and treatment, a higher number of patients are living long enough for their cancer to metastasize to the liver. This highlights a greater need for effective treatments targeting liver metastases. Additionally, advancements in personalized medicine and targeted therapies have further enhanced treatment efficacy for breast cancer led liver metastases.

Europe liver metastases treatment industry will record a promising CAGR during the forecast period, because of the aging population and increased cancer incidence rates. Enhanced healthcare infrastructure and access to advanced medical technologies have improved diagnostic capabilities, leading to earlier detection and more effective treatment options. The healthcare policies of the region focus on personalized treatment approaches, spurring the adoption of innovative therapies. Increased funding for cancer R&D contributes to the availability of new and improved treatment modalities, thus augmenting the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cancer
  - 3.2.1.2 Advancements in treatment modalities
  - 3.2.1.3 Increasing awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with medications
  - 3.2.2.2 Stringent regulatory scenarios
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Targeted therapy drugs
5.3 Chemotherapy drugs
5.4 Immunotherapy drugs

Chapter 6 Market Estimates and Forecast, By Primary Cancer, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Colorectal cancer
6.3 Breast cancer
6.4 Lung cancer
6.5 Other cancers

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Specialty pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa